Lisata Therapeutics (LSTA) Cash & Equivalents (2016 - 2025)
Historic Cash & Equivalents for Lisata Therapeutics (LSTA) over the last 13 years, with Q3 2025 value amounting to $19.0 million.
- Lisata Therapeutics' Cash & Equivalents fell 261.93% to $19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.0 million, marking a year-over-year decrease of 261.93%. This contributed to the annual value of $16.2 million for FY2024, which is 2825.65% down from last year.
- According to the latest figures from Q3 2025, Lisata Therapeutics' Cash & Equivalents is $19.0 million, which was down 261.93% from $16.8 million recorded in Q2 2025.
- Over the past 5 years, Lisata Therapeutics' Cash & Equivalents peaked at $32.4 million during Q3 2023, and registered a low of $16.2 million during Q4 2024.
- In the last 3 years, Lisata Therapeutics' Cash & Equivalents had a median value of $21.8 million in 2024 and averaged $22.6 million.
- Per our database at Business Quant, Lisata Therapeutics' Cash & Equivalents surged by 1943.01% in 2024 and then tumbled by 4049.76% in 2025.
- Over the past 3 years, Lisata Therapeutics' Cash & Equivalents (Quarter) stood at $22.6 million in 2023, then dropped by 28.26% to $16.2 million in 2024, then grew by 17.21% to $19.0 million in 2025.
- Its Cash & Equivalents stands at $19.0 million for Q3 2025, versus $16.8 million for Q2 2025 and $20.2 million for Q1 2025.